- Home
- OWLS vs EBS Comparison
OWLS vs EBS Comparison
Compare OWLS & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OWLS | EBS |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.2M | 413.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | OWLS | EBS |
|---|---|---|
| Price | $5.64 | $8.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $12.00 |
| AVG Volume (30 Days) | 24.4K | ★ 927.8K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | $6.57 | $1.29 |
| Revenue Next Year | $375.69 | N/A |
| P/E Ratio | ★ N/A | $116.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.15 | $5.62 |
| 52 Week High | $29.00 | $14.06 |
Technical Indicators
Market Signals| Indicator | OWLS | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 52.22 |
| Support Level | $5.60 | $7.77 |
| Resistance Level | $6.07 | $8.54 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 55.77 | 79.29 |
Price Performance
Historical ComparisonAbout OWLS OBOOK Holdings Inc.
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.